CGT

8개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved8 programs
CGTLimited DatastaleIstituto Clinico HumanitasPreclinical

immune evaluation (immune evaluation)

Oligorecurrent and Oligoprogressive Prostate Cancer Patients · Oligorecurrent and Oligoprogressive Pros

#OligorecurrentandOligoprogressiv#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 61Status Recruiting
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

Murine CART19 (Murine CART19)

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL; Infants With Very High Risk KMT2A B-ALL · Pediatric and Young Adult Patientswith H

#PediatricandYoungAdultPatientswi#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART-EGFRvIII T cells (CART-EGFRvIII T cells)

Patients With Residual or Reccurent EGFRvIII+ Glioma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleZhejiang UniversityPhase 1

NKG2D CAR NK and NKG2D CAR T cells (NKG2D CAR NK and NKG2D CAR T cells)

Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments · Patients With Advanced Solid Tumors With

#PatientsWithAdvancedSolidTumorsW#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting